Burden of disease and increasing prevalence of inflammatory bowel disease in a population-based cohort in the Netherlands

European Journal of Gastroenterology and Hepatology

Volumn 28, Issue 9, 2016, Pages 1065-1072

  De Groof, E Joline ^a,b   Rossen, Noortje G M ^a   Van Rhijn, Bram D ^a   Karregat, Evert P M ^a   Boonstra, Kirsten ^a,b   Hageman, Ishtu ^a   Bennebroek Evertsz, Floor ^a   Kingma, Paul J ^b   Naber, Anton H J ^b   Van Den Brande, Jan H M ^b   Mallant Hent, Rosalie C ^b   Mundt, Marco W ^b   D'Haens, Geert R A M ^a   Ponsioen, Cyriel Y ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Department of Surgery ^*  (Netherlands)

Author keywords

burden of disease; epidemiology; inflammatory bowel disease

Indexed keywords

ADALIMUMAB; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; STEROID; BIOLOGICAL PRODUCT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BIOLOGICAL THERAPY; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; EVALUATION STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL SURGERY; HEALTH CARE FACILITY; HOSPITAL PATIENT; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OUTCOME ASSESSMENT; PATIENT REFERRAL; PERIPHERAL HOSPITAL; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROCTOCOLECTOMY; QUALITY OF LIFE; STEROID THERAPY; TERTIARY CARE CENTER; ULCERATIVE COLITIS; ABDOMINAL SURGERY; ADOLESCENT; AGE DISTRIBUTION; AGED; CLINICAL TRIAL; COLITIS, ULCERATIVE; COMPARATIVE STUDY; COST OF ILLNESS; FACTUAL DATABASE; HEALTH CARE DISPARITY; HEALTH SURVEY; MIDDLE AGED; MULTICENTER STUDY; PHENOTYPE; SEVERITY OF ILLNESS INDEX; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BIOLOGICAL PRODUCTS; COLITIS, ULCERATIVE; COST OF ILLNESS; CROHN DISEASE; DATABASES, FACTUAL; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; HEALTH SURVEYS; HEALTHCARE DISPARITIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; PHENOTYPE; PREVALENCE; QUALITY OF LIFE; REFERRAL AND CONSULTATION; SEVERITY OF ILLNESS INDEX; TERTIARY CARE CENTERS; TIME FACTORS; YOUNG ADULT;

EID: 84973575958     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000660     Document Type: Article

References (27)

1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142:46-54.
2. Russel MG. Changes in the incidence of inflammatory bowel disease: what does it mean? Eur J Intern Med 2000; 11:191-196.
3. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006; 12:6102-6108.
4. Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohns disease in the Chinese population. Inflamm Bowel Dis 2004; 10:646-651.
5. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: A population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101:1274-1282.
6. Lapidus A. Crohns disease in Stockholm County during 1990-2001: An epidemiological update. World J Gastroenterol 2006; 12:75-81.
7. Rubin GP, Hungin AP, Chinn DJ, Dwarakanath D. Quality of life in patients with established inflammatory bowel disease: A UK general practice survey. Aliment Pharmacol Ther 2004; 19:529-535.
8. Rubin GP, Hungin AP, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000; 14:1553-1559.
9. Nørgard BM, Nielsen J, Fonager K, Kjeldsen J, Jacobsen BA, Qvist N. The incidence of ulcerative colitis (1995-2011) and Crohns disease (1995-2012)-based on nationwide Danish registry data. J Crohns Colitis 2014; 8:1274-1280.
10. Bösch K, Ludvigsson JF, Ekström-Smedby K, Ekbom A, Askling J, Neovius M. Nationwide prevalence of inflammatory bowel disease in Sweden: A population-based register study. Aliment Pharmacol Ther 2014; 39:57-68.
11. Russel MG, Dorant E, Volovics A, Brummer RJ, Pop P, Muris JW, et al. High incidence of inflammatory bowel disease in The Netherlands: results of a prospective study. The South Limburg IBD Study Group. Dis Colon Rectum 1998; 41:33-40.
12. Romberg-Camps MJ, Hesselink-van de Kruijs MA, Schouten LJ, Dagnelie PC, Limonard CB, Kester AD, et al. Inflammatory bowel disease in South Limburg (the Netherlands) 1991-2002: incidence, diagnostic delay, and seasonal variations in onset of symptoms. J Crohns Colitis 2009; 3:115-124.
13. Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohns and Ulcerative Colitis Associations (EFCCA) patient survey. J Crohns Colitis 2007; 1:10-20.
14. Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol 2015; 12:720-727.
15. Zankel E, Rogler G, Andus T, Reng CM, Schölmerich J, Timmer A. Crohns disease patient characteristics in a tertiary referral center: comparison with patients from a population-based cohort. Eur J Gastroenterol Hepatol 2005; 17:395-401.
16. van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut 2014; 63:72-79.
17. Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, Meijer GA. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 2007; 29:19-24.
18. Lennard-Jones JE, Shivananda S. Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol 1997; 9:353-359.
19. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473-483.
20. Brazier JE, Harper R, Jones NM, OCathain A, Thomas KJ, Usherwood T, Westlake L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305:160-164.
21. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43:29-32.
22. Harvey RF, Bradshaw JM. A simple index of Crohns-disease activity. Lancet 1980; 1:514.
23. Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut 2005; 54:782-788.
24. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998; 51:1055-1068.
25. Shivananda S, Peña AS, Mayberry JF, Ruitenberg EJ, Hoedemaeker PJ. Epidemiology of proctocolitis in the region of Leiden, The Netherlands. A population study from 1979 to 1983. Scand J Gastroenterol 1987; 22:993-1002.
26. Shivananda S, Peña AS, Nap M, Weterman IT, Mayberry JF, Ruitenberg EJ, Hoedemaeker PJ. Epidemiology of Crohns disease in Regio Leiden, The Netherlands. A population study from 1979 to 1983. Gastroenterology 1987; 93:966-974.
27. Rockwood K, Stolee P, Robertson D, Shillington ER. Response bias in a health status survey of elderly people. Age Ageing 1989; 18:177-182.